International CGT Experts Invited to Join EU-Funded Global Collaboration Hub
Crowdhelix, an open innovation platform designed to foster collaboration among researchers, academics, and industry leaders, has launched its latest Helix, the Cell and Gene Therapy Helix.
The CGT Helix has been designed to act as a platform to enable collaboration between academic researchers, R&D organisations, manufacturers and CDMO companies.
The potential of cell and gene therapy to revolutionise the treatment of cancer and genetic disorders cannot be overstated. However, the complexity associated with delivering the treatment and the need for multidisciplinary expertise, means that progress can often be slow.
The Cell and Gene Therapy Helix aims to accelerate the pace of innovation by fostering collaboration and knowledge sharing. Members of the Helix will have access to a global network of experts, funding opportunities, and the chance to collaborate on research projects.
“Our aim is to provide a collaborative environment where researchers, academics, and industry professionals can work together to develop new treatments and therapies that could benefit people across the world” said Crowdhelix CEO, Michael Browne.
“Everyone at Crowdhelix is excited at the prospect of supporting experts who are working and innovating at the cutting edge of science”. I anticipate that the Cell and Gene Therapy Helix will catalyse future collaboration and innovation in this pioneering scientific field”.
The Cell and Gene Therapy Helix will also provide members with the opportunity to share their research findings and insights with other platform users. This will help to build a community of experts who can work together to address some of the biggest challenges in cell and gene therapy.
The launch of the Cell and Gene Therapy Helix comes at a time when the field is advancing at an exceptional pace. The Gene Therapy Global Market Report 2023 estimated that the global cell and gene therapy market is expected to grow from €6 billion in 2020 to €15 billion in 2025.
“With the global cell and gene therapy market set to grow at an unprecedented rate, it’s vital that we continue to collaborate and innovate to ensure that patients have access to the most advanced treatments and therapies available,” said Dr Luc Henry, CEO of Limula and leader of the Cell and Gene Therapy Helix.
“The key challenge for Cell and Gene Therapy is to make highly personalised treatments affordable to patients. That requires innovation and collaboration beyond CGT manufacturing alone. I hope that the Helix brings multidisciplinary experts together so that we can overcome that challenge together”.
The Cell and Gene Therapy Helix is now open for membership. Researchers, academics, industry experts and regulatory professionals working in the cell and gene therapy sector are invited to join and contribute to this exciting new community.
For more information on the Cell and Gene Therapy Helix and how to join, please visit the Crowdhelix website.
This project has received funding from the European Union's Horizon Europe research and innovation programme under grant agreement No 101070922. The website reflects only the authors' view and the European Commission is not responsible for any use that may be made of the information it contains.
